Phase I Study Will Test a Peptide-Nanoparticle Chikungunya Vaccine in Healthy Adults

A newly listed Phase I trial will evaluate the safety and immune response of PepGNPChikV, a synthetic nanoparticlebased peptide vaccine candidate. The planned study is an early clinical step, not evidence that the candidate is safe or effective.

For research use only. Not for human consumption.